The Tablet version of the Ozempic of Novo injection for diabetes reached a cardiac safety objective in a study that compared it to standard treatment.
The patients who were administered oral semaglutida in addition to the standard regime suffered 21% less cardiac complications than those who received a placebo, Danish pharmaceuticals said in a statement.
While that was not enough to verify that the medicine is safer than the conventional method, it reached the objective of corroborating that it is at least equally insurance and also showed significant reductions of deaths linked to the cardiovascular system and in general.
Novo seeks to develop an oral medication that is easier to take for patients than Ozempic, their weekly injection.The drug competes with various treatments for type 2 diabetes, more common form of the disease, which reduce the risk of heart condition.
"Now we have established a solid profile of efficiency and safety of oral semaglutida and we hope to share the results with the regulatory authorities during 2019," said Mads Krogsgaard Thomsen, scientific director of Novo.
